The company is headquartered in London, UK with labs in Cambridge, UK. In January 2025, Alchemab announced an agreement with Eli Lilly and Company.

He has also held executive roles at Alchemab Therapeutics and TScan Therapeutics and spent over a decade at Eli Lilly and Company in corporate business development and global partnerships. Dr.

Big news is also expected from some of the major players; for example, Eli Lilly is aiming to conclude a phase III trial of an oral GLP-1 drug orforglipron in type 2 diabetes.

Novo Nordisk (NVO) and Eli Lilly & Co. (LLY), the global leaders in obesity medications, are now facing their first major ...

New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and ...

Some doctors are concerned that patients taking weight loss drugs like Wegovy may be losing too much lean mass. A combination ...

Shares of Verve Therapeutics skyrocketed 75% Tuesday morning after Eli Lilly announced that it would acquire the gene-editing ...

An obesity drug from China helped patients lose a lot of weight in a late-stage clinical trial, making it a prospective new ...

South Korea's trade minister Yeo Han-koo will visit the United States from June 22 to 27, the trade ministry said on Saturday ...